Equities research analysts expect that Sangamo Therapeutics Inc (NASDAQ:SGMO) will post $39.93 million in sales for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Sangamo Therapeutics’ earnings, with the lowest sales estimate coming in at $32.75 million and the highest estimate coming in at $47.10 million. Sangamo Therapeutics reported sales of $11.81 million in the same quarter last year, which indicates a positive year-over-year growth rate of 238.1%. The business is scheduled to announce its next earnings report on Thursday, November 8th.

On average, analysts expect that Sangamo Therapeutics will report full-year sales of $94.08 million for the current financial year, with estimates ranging from $50.00 million to $118.33 million. For the next financial year, analysts anticipate that the company will post sales of $98.89 million per share, with estimates ranging from $50.00 million to $129.17 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side analysts that cover Sangamo Therapeutics.

Sangamo Therapeutics (NASDAQ:SGMO) last announced its quarterly earnings results on Wednesday, August 8th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.02). Sangamo Therapeutics had a negative net margin of 105.65% and a negative return on equity of 26.36%. The firm had revenue of $21.42 million for the quarter, compared to the consensus estimate of $21.43 million. During the same period in the prior year, the business earned ($0.17) earnings per share. The company’s revenue for the quarter was up 159.6% on a year-over-year basis.

Several brokerages have recently weighed in on SGMO. Zacks Investment Research lowered shares of Sangamo Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Wednesday, May 16th. ValuEngine lowered Sangamo Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, May 8th. Wedbush reaffirmed a “hold” rating and set a $9.00 target price on shares of Sangamo Therapeutics in a research report on Tuesday, July 24th. BidaskClub raised Sangamo Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, June 20th. Finally, Bank of America initiated coverage on Sangamo Therapeutics in a research report on Wednesday, June 20th. They set a “buy” rating and a $24.00 target price on the stock. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have given a buy rating to the company’s stock. Sangamo Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $22.29.

Sangamo Therapeutics traded up $0.35, hitting $15.65, during trading on Tuesday, Marketbeat reports. 2,113,880 shares of the stock traded hands, compared to its average volume of 1,967,697. Sangamo Therapeutics has a one year low of $9.50 and a one year high of $27.50. The company has a debt-to-equity ratio of 0.07, a current ratio of 7.24 and a quick ratio of 4.78.

In other Sangamo Therapeutics news, VP Edward R. Conner sold 5,000 shares of the stock in a transaction that occurred on Monday, August 6th. The stock was sold at an average price of $13.45, for a total transaction of $67,250.00. The sale was disclosed in a filing with the SEC, which is accessible through this link. Insiders have sold a total of 30,000 shares of company stock worth $458,700 over the last ninety days. 1.20% of the stock is currently owned by corporate insiders.

A number of hedge funds have recently modified their holdings of SGMO. NumerixS Investment Technologies Inc acquired a new position in Sangamo Therapeutics during the second quarter valued at approximately $125,000. Riverhead Capital Management LLC boosted its holdings in shares of Sangamo Therapeutics by 218.0% in the second quarter. Riverhead Capital Management LLC now owns 8,267 shares of the biopharmaceutical company’s stock valued at $117,000 after buying an additional 5,667 shares during the period. Tyers Asset Management LLC boosted its holdings in shares of Sangamo Therapeutics by 301.3% in the second quarter. Tyers Asset Management LLC now owns 9,632 shares of the biopharmaceutical company’s stock valued at $137,000 after buying an additional 7,232 shares during the period. Meadow Creek Investment Management LLC boosted its holdings in shares of Sangamo Therapeutics by 301.3% in the second quarter. Meadow Creek Investment Management LLC now owns 16,856 shares of the biopharmaceutical company’s stock valued at $239,000 after buying an additional 12,656 shares during the period. Finally, Tiverton Asset Management LLC acquired a new position in shares of Sangamo Therapeutics in the second quarter valued at approximately $242,000. Institutional investors own 57.49% of the company’s stock.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc focuses on translating ground-breaking science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger DNA-binding protein (ZFP) technology enables specific genome editing and gene regulation.

Featured Story: How Do You Make Money With Penny Stocks?

Get a free copy of the Zacks research report on Sangamo Therapeutics (SGMO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.